Résumé
Objective: To date, there are no standardized disease activity tools for systemic juvenile idiopathic arthritis (sJIA). We developed a core set of disease activity measures for sJIA. Methods: We conducted a validation study in patients with sJIA recruited from 3 Canadian institutions. Disease activity scores were based on questionnaires, clinical factors, and laboratory measures. The physician's global assessment was our criterion standard. We determined the strength of association of each item with the criterion standard. We then surveyed international experts to determine the top 10 items. Finally, we used the experts' responses to generate a proposed core set of disease activity measures. Results: We enrolled 57 subjects - 26 with moderately or severely active disease, and 31 with mildly active or inactive disease. Items that most strongly correlated with the criterion standard were number of active joints (r = 0.79), parent's global assessment of disease activity (r = 0.53), erythrocyte sedimentation rate (ESR; r = 0.62), and C-reactive protein (CRP; r = 0.61). The response rate from international experts was 82% (154/187). Items with the most votes, in descending order, were number of active joints, number of days with fever in the preceding 2 weeks, patient's and parent's global assessments of disease activity, sJIA rash, ESR, CRP, and hemoglobin level. Conclusion: We propose a core set of items for measuring disease activity in sJIA. Future research should be aimed at further validation of this core set in the international context.
| Langue d'origine | English |
|---|---|
| Pages (de-à) | 115-121 |
| Nombre de pages | 7 |
| Journal | Journal of Rheumatology |
| Volume | 45 |
| Numéro de publication | 1 |
| DOI | |
| Statut de publication | Published - janv. 1 2018 |
Note bibliographique
Funding Information:From the Hospital for Sick Children, Division of Rheumatology; Dalla Lana School of Public Health, University of Toronto; Public Health Ontario; Toronto Public Health, Toronto; McMaster University, McMaster Children’s Hospital, Hamilton; School of Rural and Northern Health, Laurentian University, Sudbury, Ontario; Dalhousie University, IWK Health Centre, Halifax, Nova Scotia; McGill University, Montreal Children’s Hospital, Montreal, Quebec, Canada; University of Bristol, Bristol Royal Hospital for Children, Bristol, UK. Earlier phase of this study supported by Pfizer Inc. through an unrestricted research grant. E. Limenis, BSc, MD, University of Toronto, Hospital for Sick Children; B.M. Feldman, MD, MSc, FRCPC, University of Toronto, Hospital for Sick Children, Dalla Lana School of Public Health; C. Achonu, BSc, MHSc, Public Health Ontario; M. Batthish, MD, MSc, FRCPC, McMaster University, McMaster Children’s Hospital; B. Lang, MD, FRCPC, Dalhousie University, IWK Health Centre; M. Mclimont, BSc, MSc, Hospital for Sick Children; S. Ota, BSc, MHSc, Toronto Public Health; A. Ramanan, FRCP, University of Bristol, Bristol Royal Hospital for Children; R. Scuccimarri, MD, FRCPC, McGill University, Montreal Children’s Hospital; N.L. Young, BScPT, MSc, PhD, School of Rural and Northern Health, Laurentian University; R. Schneider, MBBCh, FRCPC, University of Toronto, Hospital for Sick Children. Address correspondence to Dr. B.M. Feldman, Division of Rheumatology, The Hospital for Sick Children, 555 University Ave., Toronto, Ontario M5G 1X8, Canada. E-mail: brian.feldman@sickkids.ca Accepted for publication May 10, 2017.
Publisher Copyright:
Copyright © 2018. All rights reserved.
ASJC Scopus Subject Areas
- Rheumatology
- Immunology and Allergy
- Immunology
PubMed: MeSH publication types
- Journal Article
- Research Support, Non-U.S. Gov't
- Validation Study